Sutro Biopharma, Inc.
NASDAQ:STROBiotechnology
+$0.32 today
- Market cap
- $141.11M
- Beta
- 1.55
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$1,174.12
Volume 0.31M
Average 0.28M
STRO Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Sutro Biopharma, Inc.NASDAQ: STRO
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables growth accelerates
Q1 FY2026 accounts payables of $2.55M (cash outflow) rose 35.4% year over year, ahead of the -534.1% change in trailing-twelve-month accounts payables. Over 3 fiscal years it compounded at +26.3% a year.
Context
- Accounts payables amounted to 2.4% of revenue in FY2025, up 1.3 pp from a year earlier.
- Accounts payables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +35.4% holds above the trailing-twelve-month pace of -534.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- (2.47M) USD
- Year-over-year change
- -449.6%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.47M) | -449.6% |
| FY2024 | 2024-12-31 | 706K | -85.3% |
| FY2023 | 2023-12-31 | 4.81M | +492.8% |
| FY2022 | 2022-12-31 | (1.23M) | -119.0% |
| FY2021 | 2021-12-31 | 6.43M | — |
Accounts Payables vs competitors
How STRO compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -534.1% is the lowest of 7, against a peer median of +151.9%.
- Accounts payables amounts to 3.1% of revenue for STRO, versus a peer median of 1284.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | €6.32M EUR | — | +17.8% | 21552.6% | |
| LTM Mar 2026 | $5.26M USD | +350.7% | +59.5% | — | |
| LTM Mar 2026 | $3.13M USD | -534.1% | +26.3% | 3.1% | |
| FY2025 | $1.62M USD | +186.9% | +62.8% | 2534.4% | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $1.4M USD | — | — | — |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $1.01M USD | +447.4% | — | — |
| LTM Mar 2026 | $343K USD | -64.3% | -51.8% | 34.3% | |
| LTM Mar 2026 | $170K USD | -60.6% | — | — | |
| LTM Mar 2026 | $17K USD | +117.0% | — | 0.0% | |
| Peer median (excluding STRO) | — | +151.9% | +38.6% | 1284.3% | |
Competitors are the stored peer set for STRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (105.54M) | (119.2M) | (106.79M) | (227.46M) | (191.09M) |
| Depreciation & Amortization | 4.84M | 5.69M | 6.82M | 7.22M | 7.32M |
| Deferred Income Tax | 7.24M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 23.24M | 26.3M | 24.91M | 24.69M | 14.01M |
| Change in Working Capital | (17.62M) | 104.41M | (34.38M) | 8.9M | (50.4M) |
| Accounts Receivables | (6.9M) | 5.34M | (28.96M) | 27.46M | 4.64M |
| Inventory | (4.55M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 6.43M | (1.23M) | 4.81M | 706K | (2.47M) |
| Other Working Capital | (12.61M) | 100.29M | (10.23M) | (19.27M) | (52.57M) |
| Other Non-Cash Items | 6.16M | (13.65M) | (2.17M) | (4.88M) | 42.92M |
| Operating Cash Flow | (81.68M) | 3.55M | (111.62M) | (191.54M) | (177.23M) |
| Capital Expenditures | (15.32M) | (7.86M) | (4.32M) | (3.1M) | (1.7M) |
| Acquisitions (Net) | 0 | 28.74M | 0 | 0 | 0 |
| Purchases of Investments | (248.73M) | (216.67M) | (460.3M) | (461.52M) | (264.95M) |
| Sales of Investments | 166.73M | 189.5M | 460.69M | 683.13M | 311.66M |
| Other Investing Activities | 9K | (28.73M) | 0 | 0 | 0 |
| Investing Cash Flow | (97.32M) | (35.02M) | (3.92M) | 218.51M | 45.01M |
| Debt Repayment | 0 | (9.38M) | (12.5M) | (4.08M) | 0 |
| Common Stock Issued | 0 | 56.27M | 11.97M | 96.53M | 376K |
| Common Stock Repurchased | (7K) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 4.25M | 1.42M | 138.08M | 1.61M | (332K) |
| Financing Cash Flow | 3.26M | 48.31M | 137.55M | 94.05M | 44K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (175.74M) | 16.84M | 22.01M | 121.02M | (132.17M) |
| Free Cash Flow | (97M) | (4.31M) | (115.93M) | (194.64M) | (178.93M) |
Sutro Biopharma, Inc.
NASDAQ:STRO
Intrinsic Alpha fair value
Locked
Current Price
$8.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.